225 related articles for article (PubMed ID: 21048365)
1. Bosentan ameliorated exercise-induced pulmonary arterial hypertension complicated with systemic sclerosis.
Yagi S; Akaike M; Iwase T; Kusunose K; Niki T; Yamaguchi K; Koshiba K; Yoshida S; Sumitomo-Ueda Y; Aihara K; Hirata Y; Dagvasumberel M; Taketani Y; Tomita N; Yamada H; Soeki T; Wakatsuki T; Matsumoto T; Sata M
Intern Med; 2010; 49(21):2309-12. PubMed ID: 21048365
[TBL] [Abstract][Full Text] [Related]
2. [Impact of bosentan therapy on stress-induced pulmonary hypertension in patients with systemic sclerosis].
Volkov AV; Kurmukov IA; Yudkina NN; Glukhova SI; Nikolaeva EV
Ter Arkh; 2015; 87(1):49-56. PubMed ID: 25823269
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment with bosentan for pulmonary hypertension and reduced peripheral circulation in juvenile systemic sclerosis.
Shimizu M; Hashida Y; Ueno K; Yokoyama T; Nakayama Y; Saito T; Ohta K; Takehara K; Yachie A
Pediatr Cardiol; 2011 Oct; 32(7):1040-2. PubMed ID: 21789477
[TBL] [Abstract][Full Text] [Related]
4. Bosentan improves skin perfusion of hands in patients with systemic sclerosis with pulmonary arterial hypertension.
Rosato E; Molinaro I; Borghese F; Rossi C; Pisarri S; Salsano F
J Rheumatol; 2010 Dec; 37(12):2531-9. PubMed ID: 20810512
[TBL] [Abstract][Full Text] [Related]
5. Bosentan for severe pulmonary arterial hypertension related to systemic sclerosis with interstitial lung disease.
Ahmadi-Simab K; Hellmich B; Gross WL
Eur J Clin Invest; 2006 Sep; 36 Suppl 3():44-8. PubMed ID: 16919010
[TBL] [Abstract][Full Text] [Related]
6. No changes in N-terminal pro-brain natriuretic peptide in a longitudinal cohort of patients with systemic sclerosis-associated pulmonary arterial hypertension on therapy with bosentan.
Rotondo C; Praino E; Nivuori M; di Serio F; Lapadula G; Iannone F
Int J Rheum Dis; 2017 Jan; 20(1):90-96. PubMed ID: 26218502
[TBL] [Abstract][Full Text] [Related]
7. Bosentan therapy of pulmonary arterial hypertension in connective tissue diseases.
Cozzi F; Montisci R; Marotta H; Bobbo F; Durigon N; Ruscazio M; Sfriso P; Iliceto S; Todesco S
Eur J Clin Invest; 2006 Sep; 36 Suppl 3():49-53. PubMed ID: 16919011
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil.
Launay D; Sitbon O; Le Pavec J; Savale L; Tchérakian C; Yaïci A; Achouh L; Parent F; Jais X; Simonneau G; Humbert M
Rheumatology (Oxford); 2010 Mar; 49(3):490-500. PubMed ID: 20015974
[TBL] [Abstract][Full Text] [Related]
9. [Two-years therapy with bosentan of pulmonary arterial hypertension related to connective tissue diseases].
Marotta H; Montisci R; Tiso F; Pontarollo S; Rizzo M; Tona F; Iliceto S; Cozzi F
Reumatismo; 2007; 59(4):299-303. PubMed ID: 18157286
[TBL] [Abstract][Full Text] [Related]
10. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.
Denton CP; Humbert M; Rubin L; Black CM
Ann Rheum Dis; 2006 Oct; 65(10):1336-40. PubMed ID: 16793845
[TBL] [Abstract][Full Text] [Related]
11. The effect of bosentan on matrix metalloproteinase-9 levels in patients with systemic sclerosis-induced pulmonary hypertension.
Giannelli G; Iannone F; Marinosci F; Lapadula G; Antonaci S
Curr Med Res Opin; 2005 Mar; 21(3):327-32. PubMed ID: 15811199
[TBL] [Abstract][Full Text] [Related]
12. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension.
Mathai SC; Girgis RE; Fisher MR; Champion HC; Housten-Harris T; Zaiman A; Hassoun PM
Eur Respir J; 2007 Mar; 29(3):469-75. PubMed ID: 17079256
[TBL] [Abstract][Full Text] [Related]
13. Bosentan: a review of its use in pulmonary arterial hypertension and systemic sclerosis.
Oldfield V; Lyseng-Williamson KA
Am J Cardiovasc Drugs; 2006; 6(3):189-208. PubMed ID: 16780392
[TBL] [Abstract][Full Text] [Related]
14. Bosentan in pulmonary arterial hypertension secondary to scleroderma.
Joglekar A; Tsai FS; McCloskey DA; Wilson JE; Seibold JR; Riley DJ
J Rheumatol; 2006 Jan; 33(1):61-8. PubMed ID: 16395751
[TBL] [Abstract][Full Text] [Related]
15. Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis.
McLaughlin V; Humbert M; Coghlan G; Nash P; Steen V
Rheumatology (Oxford); 2009 Jun; 48 Suppl 3():iii25-31. PubMed ID: 19487219
[TBL] [Abstract][Full Text] [Related]
16. Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis.
Sfikakis PP; Papamichael C; Stamatelopoulos KS; Tousoulis D; Fragiadaki KG; Katsichti P; Stefanadis C; Mavrikakis M
Arthritis Rheum; 2007 Jun; 56(6):1985-93. PubMed ID: 17530638
[TBL] [Abstract][Full Text] [Related]
17. Effects of bosentan on the skin lesions: an observational study from a single center in Japan.
Funauchi M; Kishimoto K; Shimazu H; Nagare Y; Hino S; Yano T; Kinoshita K
Rheumatol Int; 2009 May; 29(7):769-75. PubMed ID: 19037604
[TBL] [Abstract][Full Text] [Related]
18. Bosentan regulates the expression of adhesion molecules on circulating T cells and serum soluble adhesion molecules in systemic sclerosis-associated pulmonary arterial hypertension.
Iannone F; Riccardi MT; Guiducci S; Bizzoca R; Cinelli M; Matucci-Cerinic M; Lapadula G
Ann Rheum Dis; 2008 Aug; 67(8):1121-6. PubMed ID: 18029384
[TBL] [Abstract][Full Text] [Related]
19. Bosentan for the treatment of systemic sclerosis-associated pulmonary arterial hypertension, pulmonary fibrosis and digital ulcers.
Jain M; Varga J
Expert Opin Pharmacother; 2006 Aug; 7(11):1487-501. PubMed ID: 16859432
[TBL] [Abstract][Full Text] [Related]
20. An open-label, multicentre pilot study of bosentan in pulmonary arterial hypertension related to congenital heart disease.
Ibrahim R; Granton JT; Mehta S
Can Respir J; 2006; 13(8):415-20. PubMed ID: 17149459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
